Last 12 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.24 | — | 19.40 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.10 | 2.40 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 151.08 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '25 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '25 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.6% | -14.2% | — | — | — | -4.2% | -0.0% | 0.9% | 0.3% | 0.8% | 1.2% | 7.0% | — |
| — | -237.2% | — | — | — | -595.5% | -101.6% | -86.8% | — | — | — | — | — | |
| ROA | -55.8% | -10.0% | 12.5% | -390.5% | -6.0% | -0.4% | -0.0% | 0.9% | 0.3% | 0.8% | 1.2% | 6.5% | -20.7% |
| — | -2536.0% | +70603.4% | -44818.9% | -2093.4% | -147.5% | -101.5% | -86.5% | +101.4% | — | — | — | — | |
| ROIC | -92.8% | -56.7% | — | — | -40.5% | -21.1% | -0.6% | -0.2% | -0.1% | -0.1% | -0.1% | -0.2% | — |
| — | -168.8% | — | — | -53440.0% | -22961.5% | -514.7% | +2.7% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '25 | Q2 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.81 | 0.45 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.62 | 8.09 | 0.64 | 0.09 | 0.01 | 0.01 | 0.02 | 0.11 | 2.89 | 3.05 | 5.59 | 14.17 | 0.04 |
| — | +67975.0% | +3196.5% | -18.1% | -99.7% | -99.6% | -99.7% | -99.2% | +7848.2% | — | — | — | — | |
| Quick Ratio | 14.62 | 8.09 | 0.64 | 0.09 | 0.01 | 0.01 | 0.02 | 0.11 | 2.89 | 3.05 | 5.86 | 14.17 | 0.04 |
| — | +67975.0% | +3196.5% | -18.1% | -99.7% | -99.6% | -99.7% | -99.2% | +7848.2% | — | — | — | — | |
| Interest Coverage | -727.46 | -272.61 | 39.08 | -55.12 | -31.82 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 12 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PBM stock.
Psyence Biomedical Ltd.'s current P/E is -0.2x. The average P/E over the last 1 quarters is 19.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Psyence Biomedical Ltd.'s business trajectory between earnings reports.